No new drugs without research
PRA is a specialist in drug research that works with volunteers. The volunteers in the studies are healthy people, but sometimes patients as well. PRA's doctors and researchers investigate the effects of new or improved drugs as well as any side effects these may have. Extensive research on people is a compulsory step in the development of drugs. A new drug can only be launched onto the market after multiple studies with positive results.
No research without volunteers
New research would not be possible without volunteers, and that would mean there would be no new drugs for patients. That is why PRA values people like you so much, people who participate in one of the studies into a new or improved drug. Each year about 2000 people in the Netherlands take part in drug research at PRA's research centers. They are healthy volunteers, but also patients. And each person has his or her own reasons for doing this. Some do it to help somebody else, or because they receive a nice compensation for it. Whatever the reason is, PRA makes your stay at the research center as worthwhile as possible.
Specialist in bioanalysis
PRA - previously Pharma Bio Research - has been carrying out drug research in the Netherlands for more than 30 years in the research center in Groningen and in laboratories in Groningen and Assen. PRA is part of PRA Health Sciences, a worldwide network with research institutes in more than eighty countries. In this network, PRA shares the knowledge from drug research, international legislation, and bioanalysis. More than 200,000 blood and urine samples are taken each year by doctors for further investigation and analysis in a laboratory.
PRA uses the results to determine the safety, effectiveness, and long-term effects of new drugs. This makes PRA an interesting partner for drug developers and medical faculties such as University Medical Center Groningen. Other hospitals in the Netherlands and abroad also work together with PRA. These collaborations contribute to the highest possible quality of research and safety that can be achieved for patients.